Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Participants
In brief
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion of XTMAB-16 (formerly referred to as KBMAB-16) in normal healthy male and female participants.
Key facts
- Study ID
- NCT04971395
- Run by
- Xentria, Inc.
- People needed
- 25
- Starts
- 2021-06-25
- Expected to finish
- 2022-03-18
- Last updated by the study team
- 2025-01-14
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- MedStar Harbor Hospital — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.